FDA official logo
GSRS logoPFDA official logo

PRALUZATAMAB RAVTANSINE

UNII:RD2I59M9FC
Type:INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:PRALUZATAMAB RAVTANSINE
GSRS Full Record:
RD2I59M9FC
i

  • 2145115-85-9
  • ANTI-CD166 PROBODY-DRUG CONJUGATE CX-2009
  • ANTI-CD166-DM4 CX-2009
  • CX-2009
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD166 ANTIGEN (ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE)); HUMANIZED MONOCLONAL ANTIBODY; .GAMMA.1 HEAVY CHAIN HUMANIZED (1-450) (VH (HOMO SAPIENS IGHV2-5*01 (89%) (IGHD)-IGHJ4*01 (93%)) (10.7.13) (1-121)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(217)), CH3(K107>DEL(451))) (122-450)), (224-270')-DISULFIDE WITH .KAPPA. LIGHT CHAIN HUMANIZED (1'-270') (N-TERMINAL REGION (SYNTHETIC MASKING MOIETY-(1'-22')-TRIGLYCYLDISERYLDIGLYCYLSERYL LINKER-(23'-30')-CLEAVABLE MOIETY PROTEASE SUBSTRATE-CONTAINING-(31'-48')-DIGLYCYLSERYL LINKER (49'-51')))-(1'-51')-(HUMANIZED V-KAPPA (MUS MUSCULUS IGKV2-109*01 (91%) IGKJ2*03 (92%):HOMO SAPIENS IGKV2-28*01 (89%) IGKJ2*01)-(11.3.9) (52'-163')-HOMO SAPIENS IGKC*01 (164'-270')), DIMER (230-230'':233-233'')-BISDISULFIDE, SUBSTITUTED ON N6 OF 3 TO 4 LYSYL RESIDUES BY THE RADICAL RAVTASINE: 4-((5-(((2S)-1-(((1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-CHLORO-21-HYDROXY-12,20-DIMETHOXY-2,5,9,16-TETRAMETHYL-8,23-DIOXO-4,24-DIOXA-9,22-DIAZATETRACYCLO(19.3.1.110.14.03.5)HEXACOSA-1,12,14(26),16,18-PENTAENE-6-YL)OXY)-1-OXOPROPAN-2-YL)(METHYL)AMINO)-2-METHYL-5-OXOPENTAN-2-YL)DISULFANYL)BUTANOYL
  • PRALUZATAMAB RAVTANSINE [USAN]
  • Praluzatamab ravtansine [WHO-DD]
  • praluzatamab ravtansine [INN]




UNII - RD2I59M9FC | UNII Search Service